These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 31008945)

  • 1. Role of programmed cell death ligand-1 expression on prognostic and overall survival of breast cancer: A systematic review and meta-analysis.
    Li S; Chen L; Jiang J
    Medicine (Baltimore); 2019 Apr; 98(16):e15201. PubMed ID: 31008945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of programmed cell death ligand-1 expression in breast cancer: A meta-analysis.
    Zhang Y; Tian J; Qu C; Tang Z; Wang Y; Li K; Yang Y; Liu S
    Medicine (Baltimore); 2020 Dec; 99(49):e23359. PubMed ID: 33285715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Evaluation of the predictive effect of PD-L1 expression on survival in early triple-negative breast cancer].
    Yue J; Wang X; Zhu AJ; Wang DY; Gao SL; Hu NL; Si YR; Zheng FC; Ju J; Wang Z; Yuan P
    Zhonghua Zhong Liu Za Zhi; 2023 Nov; 45(11):948-954. PubMed ID: 37968080
    [No Abstract]   [Full Text] [Related]  

  • 4. Prognostic significance of programmed cell death-ligand 1 expression on circulating tumor cells in various cancers: A systematic review and meta-analysis.
    Ouyang Y; Liu W; Zhang N; Yang X; Li J; Long S
    Cancer Med; 2021 Oct; 10(20):7021-7039. PubMed ID: 34423578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis.
    Yang WF; Wong MCM; Thomson PJ; Li KY; Su YX
    Oral Oncol; 2018 Nov; 86():81-90. PubMed ID: 30409325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of programmed cell death ligand 1 (PD-L1) for hepatocellular carcinoma: a meta-analysis.
    Li XS; Li JW; Li H; Jiang T
    Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32255189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic and clinicopathological value of PD-L1 expression in primary breast cancer: a meta-analysis.
    Huang W; Ran R; Shao B; Li H
    Breast Cancer Res Treat; 2019 Nov; 178(1):17-33. PubMed ID: 31359214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Role of Programmed Death Ligand-1 Expression in Breast Cancer: A Systematic Review and Meta-Analysis.
    Li X; Li M; Lian Z; Zhu H; Kong L; Wang P; Yu J
    Target Oncol; 2016 Dec; 11(6):753-761. PubMed ID: 27422273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients.
    Tsang JY; Au WL; Lo KY; Ni YB; Hlaing T; Hu J; Chan SK; Chan KF; Cheung SY; Tse GM
    Breast Cancer Res Treat; 2017 Feb; 162(1):19-30. PubMed ID: 28058578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic and Clinicopathological Value of PD-L1 in Melanoma: A Meta-Analysis.
    Xu J; Wang F; Yan Y; Zhang Y; Du Y; Sun G
    Am J Med Sci; 2020 Jun; 359(6):339-346. PubMed ID: 32498941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of programmed cell death ligand 1 expression in patients with intrahepatic cholangiocarcinoma: a meta-analysis.
    Xian F; Ren D; Bie J; Xu G
    Front Immunol; 2023; 14():1119168. PubMed ID: 37138876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive Values of Programmed Cell Death-Ligand 1 Expression for Prognosis, Clinicopathological Factors, and Response to Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors in Patients With Gynecological Cancers: A Meta-Analysis.
    Zhang C; Yang Q
    Front Oncol; 2020; 10():572203. PubMed ID: 33634012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Implications of PD-L1 Expression in Breast Cancer: Systematic Review and Meta-analysis of Immunohistochemistry and Pooled Analysis of Transcriptomic Data.
    Matikas A; Zerdes I; Lövrot J; Richard F; Sotiriou C; Bergh J; Valachis A; Foukakis T
    Clin Cancer Res; 2019 Sep; 25(18):5717-5726. PubMed ID: 31227501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of PD-L1 in solid tumor: An updated meta-analysis.
    Wang Q; Liu F; Liu L
    Medicine (Baltimore); 2017 May; 96(18):e6369. PubMed ID: 28471952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer.
    Muenst S; Schaerli AR; Gao F; Däster S; Trella E; Droeser RA; Muraro MG; Zajac P; Zanetti R; Gillanders WE; Weber WP; Soysal SD
    Breast Cancer Res Treat; 2014 Jul; 146(1):15-24. PubMed ID: 24842267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathological and prognostic significance of programmed death ligand-1 expression in breast cancer: a meta-analysis.
    Kim HM; Lee J; Koo JS
    BMC Cancer; 2017 Oct; 17(1):690. PubMed ID: 29041905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of programmed cell death ligand 1 expression in patients with head and neck cancer: A systematic review and meta-analysis.
    Li J; Wang P; Xu Y
    PLoS One; 2017; 12(6):e0179536. PubMed ID: 28604812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Role and Clinical Significance of Tumor-Infiltrating Lymphocyte (TIL) and Programmed Death Ligand 1 (PD-L1) Expression in Triple-Negative Breast Cancer (TNBC): A Systematic Review and Meta-Analysis Study.
    Lotfinejad P; Asghari Jafarabadi M; Abdoli Shadbad M; Kazemi T; Pashazadeh F; Sandoghchian Shotorbani S; Jadidi Niaragh F; Baghbanzadeh A; Vahed N; Silvestris N; Baradaran B
    Diagnostics (Basel); 2020 Sep; 10(9):. PubMed ID: 32957579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic role and clinical significance of tumor-infiltrating lymphocyte (TIL) and programmed death ligand 1 (PD-L1) expression in gastric cancer: a systematic review and meta-analysis.
    Ren J; He Q; Yin H; Zheng L; Li L; Wu X
    Clin Transl Oncol; 2023 May; 25(5):1436-1445. PubMed ID: 36528835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome.
    Arias-Pulido H; Cimino-Mathews A; Chaher N; Qualls C; Joste N; Colpaert C; Marotti JD; Foisey M; Prossnitz ER; Emens LA; Fiering S
    Breast Cancer Res Treat; 2018 Sep; 171(2):273-282. PubMed ID: 29858752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.